Biomedical molecular data firm Elucidata on Thursday said it has raised USD 5 million (around Rs 36 crore) in a funding round led by IvyCap Ventures. The pre-Series A funding round also saw participation from Hyperplane Venture Capital and a few angel investors, Elucidata said in a statement. The funding will enable the company to capitalise on its position as a leading provider of structured biomedical molecular data to the life sciences industry, it added.
“In the pharma industry, biomedical data of drug discovery is increasing in diversity and volume at a rapid rate. In this scenario, it gives us immense pleasure to collaborate with a team which is driven by a vision of drug discovery and pharma R&D,” IvyCap Ventures founder and Managing Partner Vikram Gupta said.
Also read: 99% of Businesses in India Implement Digital Online Strategy to Recognise their Customers; Highest in APAC: Experian Report
On the funding, Elucidata co-founder and CEO Abhishek Jha said: “The strong backing from IvyCap Ventures and Hyperplane would amplify our ability to help our partners improve in their data-driven drug discovery”.